相关实验视频

Updated: Jun 1, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

纳灵宁通过STAT3-MGST2信号通路诱导骨髓瘤细胞中的铁亡

Yingang Li^1,2, Xizhuang Bai²

¹China Medical University, Shenyang, Liaoning, China.

Journal of bone oncology

|January 21, 2025

概括

纳灵宁是一种黄类化合物,通过诱导细胞死亡的一种形式铁亡,有效地对抗骨质肉瘤. 它针对STAT3-MGST2通路,为这种攻击性癌症提供了一个有前途的新治疗策略.

科学领域:

在瘤学瘤学.
生物化学生化学
分子生物学分子生物学

背景情况:

骨髓瘤是一种流行青少年癌症,具有高转移潜力和不良预后.
铁亡,一个由铁积累和脂质过氧化驱动的受调细胞死亡途径,呈现出一种新的治疗标.
纳灵宁是一种具有已知的抗癌作用的黄类化合物,尚未在骨髓瘤中得到广泛研究.

研究的目的:

为了研究纳灵宁对骨髓瘤细胞的抗癌作用.
阐明潜在的分子机制,包括涉及的铁灭诱导和信号通路.
在临床前骨髓瘤模型中评估纳灵宁的治疗潜力.

主要方法:

进行了细胞活力测定,反应性氧物种 (ROS) 检测,铁积累和甲 (MDA) 测量.
生物信息学分析发现微小体谷氨酸S转移酶2 (MGST2) 在骨髓瘤中表达高.
基因沉默,西部抹杀和体内异种移植模型被用于探索STAT3-MGST2通路和治疗疗效.

主要成果:

纳灵宁显著降低了骨髓瘤细胞活力,增加了ROS,铁过载和MDA水平,表明铁灭诱导.
发现MGST2的升高调节和沉默增强了ferroptosis的敏感性,并减少了瘤细胞的增殖,迁移和入侵.
纳灵宁抑制了STAT3-MGST2信号通路,抑制了MGST2转录,这种效应被STAT3激动剂逆转. 在体内研究证实了naringenin对瘤生长的抑制.

结论:

纳灵宁通过STAT3-MGST2信号通路诱导骨髓瘤细胞中的铁亡.
用纳灵宁向STAT3-MGST2通路是骨髓瘤的一种有前途的治疗策略.
在临床前模型中,纳灵宁表现出显著的抗瘤活性和良好的生物安全性.

关键词:

铁化是铁化的一种.这就是MGST2的原因.在Naringenin,我们可以看到.骨质肉瘤骨质肉瘤是什么在STAT3中,我们可以使用STAT3.

更多相关视频

Preparation of Naringenin Solution for In Vivo Application

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

相关概念视频

Necrosis

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...